Findings

What do systematic reviews say?

2,038 questions · 2,118 findings · 339 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 323 · 15.3%GRADE not reported 166 · 7.8%Very low 552 · 26.1%Low 592 · 28%Moderate 340 · 16.1%High 145 · 6.8%

Nonselective beta‐blockers vs placebo

Withdrawals due to adverse events · adults with primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of nonselective beta‐blockers for primary hypertension 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 729 participants
Low

Dihydropyridine calcium channel blockers vs placebo

Variation in the decrease in 24‐hour ambulatory hourly SBP (at 3 to 12 weeks) · adults with primary hypertension

1 finding from 1 review

Time course for blood pressure lowering of dihydropyridine calcium channel blockers 2014 · Cochrane Headline outcomes only
no estimate extracted
16 studies · 2768 participants
Moderate

Dihydropyridine calcium channel blockers vs placebo

Variation in the decrease in 24‐hour ambulatory hourly DBP (at 3 to 12 weeks) · adults with primary hypertension

1 finding from 1 review

Time course for blood pressure lowering of dihydropyridine calcium channel blockers 2014 · Cochrane Headline outcomes only
no estimate extracted
16 studies · 2768 participants
Moderate

Intervention not reported

LDL‐Cholesterol rosuvastatin 2.5 mg/day · participantswith normal or abnormal lipid profiles

1 finding from 1 review

Rosuvastatin for lowering lipids 2014 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 450 participants
Low

Intervention not reported

LDL‐Cholesterol rosuvastatin 5 mg/day · participantswith normal or abnormal lipid profiles

1 finding from 1 review

Rosuvastatin for lowering lipids 2014 · Cochrane Headline outcomes only
no estimate extracted
25 studies · 2602 participants
High

Intervention not reported

LDL‐Cholesterol rosuvastatin 10 mg/day · participantswith normal or abnormal lipid profiles

1 finding from 1 review

Rosuvastatin for lowering lipids 2014 · Cochrane Headline outcomes only
no estimate extracted
74 studies · 9855 participants
High

Intervention not reported

LDL‐Cholesterol rosuvastatin 20 mg/day · participantswith normal or abnormal lipid profiles

1 finding from 1 review

Rosuvastatin for lowering lipids 2014 · Cochrane Headline outcomes only
no estimate extracted
28 studies · 3675 participants
High

Intervention not reported

LDL‐Cholesterol rosuvastatin 40 mg/day · participantswith normal or abnormal lipid profiles

1 finding from 1 review

Rosuvastatin for lowering lipids 2014 · Cochrane Headline outcomes only
no estimate extracted
18 studies · 3512 participants
High

Intervention not reported

WDAE2 all doses · participantswith normal or abnormal lipid profiles

1 finding from 1 review

Rosuvastatin for lowering lipids 2014 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 1330 participants
Very low

Intervention not reported

Death or lost to care · HIV infected patients

The intervention probably leads to lower death or lost to care (moderate certainty).

1 finding from 1 review

Decentralising HIV treatment in lower‐ and middle‐income countries 2013 · Cochrane Headline outcomes only
RR 0.46 [0.29, 0.71]
4 studies · 39090 participants
Moderate

Intervention not reported

Lost to care · HIV infected patients

The intervention may leads to lower lost to care (low certainty).

1 finding from 1 review

Decentralising HIV treatment in lower‐ and middle‐income countries 2013 · Cochrane Headline outcomes only
RR 0.55 [0.45, 0.69]
4 studies · 39090 participants
Low

Intervention not reported

Death · HIV infected patients

The intervention may leads to lower death (low certainty).

1 finding from 1 review

Decentralising HIV treatment in lower‐ and middle‐income countries 2013 · Cochrane Headline outcomes only
RR 0.34 [0.13, 0.87]
4 studies · 39090 participants
Low

Intervention not reported

Death or lost to care · HIV infected patients

It is very uncertain whether the intervention changes death or lost to care (very low certainty).

1 finding from 1 review

Decentralising HIV treatment in lower‐ and middle‐income countries 2013 · Cochrane Headline outcomes only
RR 0.7 [0.47, 1.02]
4 studies · 56360 participants
Very low

Intervention not reported

Lost to care · HIV infected patients

The intervention probably leads to lower lost to care (moderate certainty).

1 finding from 1 review

Decentralising HIV treatment in lower‐ and middle‐income countries 2013 · Cochrane Headline outcomes only
RR 0.3 [0.17, 0.54]
4 studies · 56360 participants
Moderate

Intervention not reported

Death · HIV infected patients

It is very uncertain whether the intervention changes death (very low certainty).

1 finding from 1 review

Decentralising HIV treatment in lower‐ and middle‐income countries 2013 · Cochrane Headline outcomes only
RR 1.1 [0.63, 1.92]
4 studies · 55099 participants
Very low

Intervention not reported

Death or lost to care · HIV‐infected patients

The intervention showed no clear difference in death or lost to care (moderate certainty).

1 finding from 1 review

Decentralising HIV treatment in lower‐ and middle‐income countries 2013 · Cochrane Headline outcomes only
RR 0.95 [0.62, 1.46]
2 studies · 709 participants
Moderate

Intervention not reported

Lost to care · HIV‐infected patients

The intervention showed no clear difference in lost to care (moderate certainty).

1 finding from 1 review

Decentralising HIV treatment in lower‐ and middle‐income countries 2013 · Cochrane Headline outcomes only
RR 0.81 [0.3, 2.21]
2 studies · 709 participants
Moderate

Intervention not reported

Death · HIV‐infected patients

The intervention showed no clear difference in death (moderate certainty).

1 finding from 1 review

Decentralising HIV treatment in lower‐ and middle‐income countries 2013 · Cochrane Headline outcomes only
RR 1.03 [0.64, 1.65]
2 studies · 709 participants
Moderate